1. Clinical & Scientific Overview
Oxybutynin Chloride (TIP-MED-000427, Reference Code [12.10]-C157) is classified under
Urological & Renal Stone Medicines (Ch 12) as a Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smooth-Muscle Antispasmodic.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [12.10] (Tolterodine Tartrate, Oxybutynin Chloride & Flavoxate). Representative Indian Market Examples (Edition 2.7 Ch 12 [12.10], p. 159): Tolterodine: Roliten / Roliten-OD (Sun — 1 mg, 2 mg IR; 2 mg, 4 mg LA), Terol-LA (Cipla); Oxybutynin: Cystran (Intas — 2.5 mg, 5 mg), Tropan; Flavoxate: Urispas (Walter Bushnell — 200 mg) — Strengths & Dosage Forms: Tolterodine IR Tablets: 1 mg, 2 mg; ER Capsules: 2 mg, 4 mg. Oxybutynin Tablets: 2.5 mg, 5 mg (Scored), 5 mg ER. Flavoxate Film-Coated Tablets: 200 mg.
Tolterodine IR Tablets: 1 mg, 2 mg; ER Capsules: 2 mg, 4 mg. Oxybutynin Tablets: 2.5 mg, 5 mg (Scored), 5 mg ER. Flavoxate Film-Coated Tablets: 200 mg.
3. Mechanism of Action & Pharmacodynamics
Tolterodine and Oxybutynin block bladder detrusor M2/M3 receptors to suppress involuntary contractions; Flavoxate exerts direct phosphodiesterase smooth-muscle spasmolysis with minimal anticholinergic effect.
4. Therapeutic Indications & Evidence-Supported Uses
- Overactive bladder (urge urinary incontinence, urgency, frequency), neurogenic detrusor overactivity (Oxybutynin), and symptomatic relief of dysuria, nocturia, and suprapubic cystitis/catheter spasm (Flavoxate)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Tolterodine: 2 mg PO BD (IR) or 4 mg PO OD (ER). Oxybutynin: 2.5–5 mg PO BD–TDS (max 20 mg/day). Flavoxate: 200 mg PO TDS–QDS after meals.
Administration & Meal Timing: Take Flavoxate after meals to prevent nausea; swallow Tolterodine ER capsules whole with water. | Once daily (Tolterodine ER) or BD/TDS (IR formulations & Flavoxate).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [12.10].
Renal: Reduce Tolterodine to 1 mg BD (or 2 mg ER OD) if CrCl <30 mL/min. Hepatic: Reduce Tolterodine to 1 mg BD in Child-Pugh B; avoid in Child-Pugh C.
Renal: Reduce Tolterodine to 1 mg BD (or 2 mg ER OD) if CrCl <30 mL/min. Hepatic: Reduce Tolterodine to 1 mg BD in Child-Pugh B; avoid in Child-Pugh C.
Renal: Reduce Tolterodine to 1 mg BD (or 2 mg ER OD) if CrCl <30 mL/min. Hepatic: Reduce Tolterodine to 1 mg BD in Child-Pugh B; avoid in Child-Pugh C.
7. Contraindications, Precautions & High-Risk Warnings
- CONTRAINDICATED IN URINARY RETENTION, GASTRIC RETENTION & UNCONTROLLED NARROW-ANGLE GLAUCOMA: Oxybutynin is highly lipophilic, crosses the blood–brain barrier, and carries a high Anticholinergic Cognitive Burden (ACB Score = 3 — avoid in frail elderly/dementia per AGS Beers 2023; prefer Mirabegron or Solifenacin).
Key Clinical Precautions: Renal: Reduce Tolterodine to 1 mg BD (or 2 mg ER OD) if CrCl <30 mL/min. Hepatic: Reduce Tolterodine to 1 mg BD in Child-Pugh B; avoid in Child-Pugh C.
8. Adverse Effects Profile
- Dry mouth (xerostomia — up to 35–70% with Oxybutynin), constipation, blurred vision, dry eyes, drowsiness, dizziness, heat intolerance (anhidrosis).
- Acute urinary retention (especially in men with BPH), delirium/cognitive decline in older adults, acute angle-closure glaucoma, QTc prolongation (Tolterodine).
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CYP3A4 inhibitors (Clarithromycin, Itraconazole, Ketoconazole) double Tolterodine/Oxybutynin levels (cap Tolterodine at 2 mg/day)
- Antagonises cholinesterase inhibitors (Donepezil — 'prescribing cascade' worsening dementia!)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [12.10].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Sip water or use sugar-free lozenges for dry mouth; avoid overheating in Indian summer weather (reduced sweating); report difficulty passing urine or confusion in elderly patients immediately.
- Meal & Clock Timing Instruction: Take Flavoxate after meals to prevent nausea; swallow Tolterodine ER capsules whole with water. (Once daily (Tolterodine ER) or BD/TDS (IR formulations & Flavoxate).)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM (Standard Urology OPD) | Compendia: NFI 7th Ed 2026 / AGS Beers Criteria 2023
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tolterodine IR Tablets: 1 mg, 2 mg; ER Capsules: 2 mg, 4 mg. Oxybutynin Tablets: 2.5 mg, 5 mg (Scored), 5 mg ER. Flavoxate Film-Coated Tablets: 200 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.10]-C158 Flavoxate Hydrochloride — Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smoo
- [12.10]-CMP159 Drotaverine Hydrochloride IP — Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smoo
- [12.11]-C160 Disodium Hydrogen Citrate — Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors
- [12.11]-CMP161 Phenazopyridine Hydrochloride IP — Systemic & Urinary Alkalinisers / Urolithiasis Inhibitors